Rafael Fonseca, MD

Panelists discuss how recent therapeutic advances, including novel drug combinations and personalized treatment approaches, are reshaping the standard of care for patients with newly diagnosed multiple myeloma (NDMM) while emphasizing the importance of risk stratification and early intervention strategies.

Rafael Fonseca, MD, envisions a future where bispecific antibodies and CAR T-cell therapy, currently used in advanced stages of multiple myeloma treatment, can offer potential cure for patients, and emphasizes the importance of advocating for their broader application in community settings.

An expert oncologist discusses novel treatments for relapsed/refractory multiple myeloma presented at recent meetings, highlighting a study on elranatamab, a new compound targeting BCMA, and trials including the LINKER-MM1 study on linvoseltamab.

Rafael Fonseca, MD, discusses the sequencing of CAR-T and bispecific antibodies in patients with relapsed/refractory multiple myeloma and tailoring treatment based on prior medical history for elderly and frail individuals.

Dr Fonseca shares findings from the MonumenTAL-1 trial presented at ASCO 2023, suggesting potentially reduced infection rates in patients with relapsed/refractory multiple myeloma receiving talquetamab relative to BCMA-targeted agents.

Dr Rafael Fonesca reviews data from the TriMM-2 study presented at ASCO 2023 investigating combination talquetamab plus daratumumab for patients with relapsed/refractory multiple myeloma, highlighting a 78% response rate to talquetamab, but noting side effects like CRS and infections.

Rafael Fonseca, MD, emphasizes the considerations of selecting therapies targeting specific markers like BCMA and GPRC5D in patients with relapsed/refractory multiple myeloma, such as prior exposures, efficacy, and potential side effects.

Dr Fonseca discusses the prognosis of a patient with relapsed/refractory multiple myeloma, noting the patient's history with treatments like venetoclax and dexamethasone, and the ultimate decision to switch to talquetamab, a GPRC5D-directed bispecific antibody.

Rafael Fonseca, MD, presents the clinical case of a 66-year-old man with relapsed/refractory multiple myeloma for review.

Before closing out his discussion on transplant-ineligible multiple myeloma, Rafael Fonseca, MD, considers the future roles of CAR T-cell and bispecific antibody therapies.

Expert perspectives on two bispecific antibodies, teclistamab and talquetamab, that have been investigated in multiply relapsed multiple myeloma.

Shared insight on two novel CAR T-cell therapies, cilta-cel and ide-cel, that have been tested in multiply relapsed multiple myeloma.

Rafael Fonseca, MD, shares an overview of the treatment armamentarium for patients with relapsed/refractory multiple myeloma.

Practical advice on strategies to improve care for patients with transplant-ineligible multiple myeloma regarding induction and maintenance therapy, and aiming for deep and durable responses.

Expert perspectives on updated data from the MAIA trial in newly diagnosed transplant-ineligible multiple myeloma and how this can be applied to clinical practice.

Rafael Fonseca, MD, provides details on a patient case of transplant-ineligible multiple myeloma and reviews the selection of frontline triplet versus doublet therapy.

Rafael Fonseca, MD, reviews efficacy and safety data from the phase 3 MAIA trial and discusses their implications for clinical practice.

Rafael Fonseca, MD, discusses the role of monoclonal antibodies in the first-line setting in patients with newly diagnosed multiple myeloma.

Rafael Fonseca, MD, reviews first-line therapy options and considerations for treatment selection for patients with newly diagnosed multiple myeloma.

Rafael Fonseca, MD, discusses the challenges of treating patients with newly diagnosed multiple myeloma.

Rafael Fonseca, MD, reviews the case overview of a 77-year-old woman with multiple myeloma.

Rafael Fonseca, MD, discusses the case of a 77-year-old woman with multiple myeloma, treatment approach for patients with newly diagnosed multiple myeloma, and the trials providing insight into the treatment of this disease.

During a virtual Targeted Oncology Case-Based Roundtable event, Rafael Fonseca, MD, lead a discussion on how MRD status can guide treatment of multiple myeloma